Treatment of Staphylococcal Skin Infections in Pediatric Patients

Initial Antibiotic Selection Based on Infection Severity

For uncomplicated staphylococcal skin infections in children, first-line treatment is cephalexin 25 mg/kg/day divided into 4 doses for methicillin-susceptible S. aureus (MSSA), with clindamycin or vancomycin reserved for confirmed or suspected MRSA based on local resistance patterns and clinical severity 1
Cephalexin 25 mg/kg/day divided into 4 doses is the oral agent of choice for MSSA infections, according to the Infectious Diseases Society of America 2, 1
Dicloxacillin 25 mg/kg/day in 4 divided doses is equally effective for MSSA infections 2
For suspected community-acquired MRSA (CA-MRSA), clindamycin 10-20 mg/kg/day in 3 divided doses orally is preferred if local clindamycin resistance rates are <10% 2, 1, 3
TMP-SMX 8-12 mg/kg/day (based on trimethoprim component) in 2 divided doses is an alternative for CA-MRSA 2, 1

For MSSA infections, nafcillin 50 mg/kg/dose IV every 4-6 hours is recommended 1
Cefazolin 33 mg/kg/dose IV every 8 hours can be used if penicillin allergy is not type 1 hypersensitivity 1, 3
For confirmed or suspected MRSA, vancomycin 40 mg/kg/day in 4 divided doses IV (or 15 mg/kg/dose every 6 hours) is the parenteral drug of choice 2, 1, 3
Indications for vancomycin include critically ill patients, failure to improve on beta-lactam therapy after 24-48 hours, high local MRSA prevalence, or confirmed MRSA on culture 3

Initial empiric therapy for Staphylococcal Scalded Skin Syndrome (SSSS) should be an anti-staphylococcal beta-lactam (cefazolin or nafcillin) 3
Clindamycin 10-13 mg/kg/dose IV every 6-8 hours should be added as adjunctive therapy to suppress exotoxin production at the ribosomal level 3
Tetracyclines (doxycycline, minocycline) should not be used in children <8 years of age 2, 1, 3

Mupirocin 2% topical ointment is recommended for localized minor staphylococcal skin infections 3
A 5-day decolonization regimen including intranasal mupirocin twice daily, daily chlorhexidine washes, and daily decontamination of personal items is recommended for recurrent S. aureus infections 1

The American Academy of Pediatrics recommends clindamycin 10–20 mg/kg/day divided into three doses for children with outpatient MRSA infections when local clindamycin resistance is < 10% (moderate evidence). 4
The Infectious Diseases Society of America (IDSA) lists trimethoprim‑sulfamethoxazole 8–12 mg/kg/day (based on trimethoprim) divided into two doses as an alternative oral option for outpatient MRSA (moderate evidence). 5
The American Academy of Pediatrics advises against using TMP‑SMX as monotherapy for cellulitis because of inadequate streptococcal coverage (moderate evidence). 4

The IDSA recommends cefazolin 33 mg/kg IV every 8 hours for MSSA infections in children who have a non‑type 1 penicillin allergy (moderate evidence). 5

The IDSA states that a 7‑day course is sufficient for uncomplicated pediatric skin infections (moderate evidence). 5
Therapy should be extended beyond 5–7 days if clinical improvement has not occurred (moderate evidence). 5

The American Academy of Pediatrics cautions against the use of tetracyclines (e.g., doxycycline, minocycline) in children younger than 8 years due to the risk of tooth discoloration (moderate evidence). 4

For animal or human bite injuries, the IDSA recommends amoxicillin‑clavulanate to provide polymicrobial coverage, including anaerobes (moderate evidence). 6
In immunocompromised pediatric patients, clinicians should consider broader gram‑negative and anaerobic antimicrobial coverage (moderate evidence). 5

The American Academy of Pediatrics advises that purely localized furunculosis can be treated with incision and drainage alone, without systemic antibiotics (moderate evidence). 4